Treatments for obesity

Bibliography

• NORTH AMERICAN ASSOCIATION FOR THE STUDY OF OBESITY: Guidelines for the approval and use of drugs to treat obesity. Obesity Res. (1995) 3:473–478.
   PubMedGoogle Scholar
• KUCZMARSKI RJ, FLEGAL KM, CAMPBELL SM, JOHNSON CL: Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Survey 1960-1991. JAMA (1994) 272:205–211.
   PubMed Web of Science ®Google Scholar
• SANNES LJ: Obesity: prospects for emerging therapies. Decision Resources (November 1995).
   Google Scholar
• OSTBYE T, POMERLEAUJ, SPEECHLEY M: Correlates of body mass index in the 1990 Ontario Health Survey. Can. Med. Assoc. 1 (1995) 152(11):1811–1817.
   Google Scholar
• GOLDSTEIN DJ, POTVIN J: Long-term weight loss: effect of pharmacological agents. Am. Clin. Nutr. (1994) 60:647–657.
   PubMed Web of Science ®Google Scholar
• This is a thorough review of the long-term treatment with existing treatments.
   Google Scholar
• GOLDSTEIN DJ, POTVIN J: Long-term weight loss: effect of pharmacological agents. Am. Clin. Nutr. (1994) 60:647–657.
   PubMed Web of Science ®Google Scholar
• Build and Pressure Study 1979. Society of Actuaries and Association of Life Insurance Medical Directors of America, Chicago (1980).
   Google Scholar
• Bostrom H, Ljungstedt N (Eds.), Almquist and Wiksell International, Stockholm (1981):182–198.
   Google Scholar
• LEW EA: Mortality and weight: insured lives and the American Cancer Society studies. Ann. Intern. Med. (1985) 103:1024–1029.
   PubMed Web of Science ®Google Scholar
• WAALER HT: Height, weight, and mortality - the Norwegian experience. Acta Med. Scand. SuppL (1984) 679:1–56.
   PubMedGoogle Scholar
• GARRISON RJ, FEINLIEB M, CATELLI WP, MCNAMARA PM: Cigarette smoking as a confoun-der of the relationship between relative weight and long-term mortality in the Framingham Study. JAMA (1983) 249:2199–203.
   PubMed Web of Science ®Google Scholar
• EPSTEIN FH, FRANCIS T, HAYNER NS, et al.: Prevalence of chronic diseases and distribution of selected physiologic variables in a total community. Tecumseh, Michigan. Am. I Epidemiol. (1965) 81:301–322.
   Google Scholar
• VAN ITALLIE TB: Obesity: adverse effects on health and longevity. Am. I Clin. Nutr. (1977) 32:2723–2733.
   Web of Science ®Google Scholar
• MANSON JE, WILLETT WC, STAMPFER MJ, et al.: Body weight and mortality among women. New Engl. I Med. (1995) 333:677–685.
   PubMed Web of Science ®Google Scholar
• VAN ITALLIE TB: Health implication of overweight and obesity in the United States. Ann. Intern. Med. (1985) 103:983–988.
   PubMed Web of Science ®Google Scholar
• PUBLIC HEALTH SERVICE: Report of the Hypertension Task Force (Volume 9). US Department of Health, Education and Welfare, Bethesda, MD (1979). NIH Publication 79–1631.
   Google Scholar
• WEISS YA, SAFAR ME, LONDON GM, et al.: Repeat hemodynamic determinations in borderline hypertension. Am. I Med. (1978) 64:382–387.
   Web of Science ®Google Scholar
• PAFFENBARGER RS, RHORNA MC, WING SL: Chronic disease in former college students. VIII. Characteristics in youth predisposing to hypertension in later years. Am. I Epidemiol. (1968) 88:25–30.
   PubMed Web of Science ®Google Scholar
• Bray GA (Ed.), US Department of Health, Education and Welfare, Bethesda, MD (1979). NIH Publication 79–359:125–163.
   Google Scholar
• KANNELL WB, GORDON T, OFFUTT D: Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann. Intern. Med. (1969) 71:89–105.
   PubMed Web of Science ®Google Scholar
• HUBERT HB, FEINLIEB M, MCNAMARA PM, CASTELLI WP: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation (1983) 67:968–977.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA, COOKE CR, ANDRES R, FALLONA GR, DAVIS PJ: The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. I Clin. Invest. (1975) 55:845–855.
   PubMed Web of Science ®Google Scholar
• DORNFELD LP, MAXWELL MH, WAKS A, TUCK ML: Mechanisms of hypertension in obesity. Kidney InL Suppl. (1987) 22:S254–258.
   PubMedGoogle Scholar
• ALLBRINK MJ, MEIGS JVV, GRANOFF MA: Weight gain and serum triglycerides in normal men. New Engl. I Med. (1962) 266:484–489.
   PubMed Web of Science ®Google Scholar
• Bjorntorp P, Brodoff BN (Eds.), JB Lippincott Co., New York (1992):502–511.
   Google Scholar
• MANSON JE, COLDITZ GA, STEMPFER MJ, et al.: A prospective study of obesity and risk of coronary heart disease in women. New Engl. I Med. (1990) 322:882–889.
   PubMed Web of Science ®Google Scholar
• LINDSTEDT K, TONSTAD S, KUZMA JW: Body mass index and patterns of mortality among Seventh-Day Adventist men. Int. I Obesity (1991) 15:397–406.
   PubMed Web of Science ®Google Scholar
• Bray G, Bouchard C, James P (Eds.), Marcel Decker, Inc., Philadelphia (1997).
   Google Scholar
• UNITED STATES NATIONAL COMMISSION ON DIABETES: Report of the National Commis-sion on Diabetes to the Congress of the United States. US Department of Health, Education and Welfare, Bethesda, MD (1975). Publication no. 76–1021, Volume 1.
   Google Scholar
• HARRIS MI, HADDEN WC, KNOWLER WVC, BENNETT PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population ages 20-74 yr. Diabetes (1987) 36:523–534.
   PubMed Web of Science ®Google Scholar
• HARTZ AJ, RUPLEY DC, KALKHOFF RD, RIMM A: Relationship of obesity to diabetes: influences of obesity level and body fat distribution. Prey. Med. (1983) 12:351–357.
   PubMed Web of Science ®Google Scholar
• KALKHOFF RK, HARTZ AH, RUPLEY D, KISSEBAH AH, KELBER S: Relationship of body fat distribution to blood pressure, carbohydrate intolerance, and plasma lipids in healthy obese women. J. Lab. Clin. Med. (1983) 102:621–627.
   PubMedGoogle Scholar
• REMMERS JE, DEGROOT WJ, SAUERLAND EK, ANCH AM: Pathogens of upper airway occlusion during sleep. J. AppL Physiol. (1978) 44:931–938.
   PubMed Web of Science ®Google Scholar
• KOPELMAN PG, APPS MC, COPE T, et al.: Nocturnal hypoxia and sleep apnea in asymptomatic obese men. Int. J. Obesity (1986) 10:211–217.
   PubMed Web of Science ®Google Scholar
• SHARP JR, BARROCAS M, CHOKROVERTY S: The cardiorespiratory effects of obesity. Clin. Chest Med. (1980) 1:103–118.
   PubMed Web of Science ®Google Scholar
• LEW EA, GARFINKEL L: Variations in mortality by weight among 750,000 men and women. J. Chron. Dis. (1979) 32:563–576.
   PubMedGoogle Scholar
• HULKA BS, EDISON TI, LININGER R: Steroid hormones and risks of breast cancer. Cancer Suppl. (1994) 74:1111–1124.
   PubMed Web of Science ®Google Scholar
• LEACH RE, BAUMGARD S, BROOM J: Obesity: its relationship to osteoarthritis of the knee. Clin. Orthop. (1973) 93:271–273.
   PubMed Web of Science ®Google Scholar
• FELSON D: Weight and osteoarthritis. J. Rheumatology (1995) 22(43 Suppl.):75–95.
   Web of Science ®Google Scholar
• ANDERSON J, FELSTON DT: Factors associated with osteoarthritis of the knee in the first National Health and Nutrition Examination Survey. Am. J. EpidemioL (1988) 128:179–189.
   PubMed Web of Science ®Google Scholar
• HELIOVARA M, MAKELA M, IMPIVARA O, et al.: Association of overweight, trauma and workload with COXARTHRTHTOSIS. A Health survey of 7,217 persons. Acta Orthop. Scand. (1993) 64:513–518.
   PubMedGoogle Scholar
• RIMM AA, WERNER HY, YSERLOO BY, BERNSTEIN RA: Relationship of obesity and disease in 73,532 weight-conscious women. Public Health Report (1975) 90:44–54.
   PubMed Web of Science ®Google Scholar
• CANADA HEALTH PROMOTION DIRECTORATE: Canadian Guidelines for Healthy Weights. Minister of National Health and Welfare, Ottawa (1988).
   Google Scholar
• HEALTH AND WELFARE CANADA: Canada Health Survey. Health and Welfare Canada, Ottawa (1978).
   Google Scholar
• WASSERTHEI-SMOLLE R, OBERMSAN A, BLAUFOX MD, DAVIS B, LANGFORD H: The trial of antihypertensive interventions and management (TIA1VI) study. Final results with regard to blood pressure, cardiovascular risk and quality of life. Am. I Hypertens. (1992) 5:37–44.
   PubMed Web of Science ®Google Scholar
• KATZEL KI, BLEECKER EU, COLMAN EG, et al.: Effects of weight loss vs. aerobic exercise training on risk factors for coronary disease in healthy obese, middle-aged and older men. JAMA (1995) 274:1915–1921.
   PubMed Web of Science ®Google Scholar
• FOLEY E, BENOTTI P, BORLASE B, HOLLINGSHEAD J, BLACKBURN GL: Impact of gastric restrictive surgery on hypertension in the morbidly obese. Am. I Surg. (1992) 163:294–297.
   PubMed Web of Science ®Google Scholar
• DATILLO AM, KRIS-ETHERTON PM: Effects of weight reduction on blood lipids and lipopro-teins: a meta-analysis. Am. J. Clin. Nutr. (1992) 56:320–328.
   PubMed Web of Science ®Google Scholar
• VASWANI AN: Effect of weight reduction on circulating lipids: an integration of possible mechanisms. Am. Coll. Nutr. (1983) 2:123–132.
   PubMed Web of Science ®Google Scholar
• LEVOVITZ H, MANERGI M, CHAIKEN R: The relationship between type II diabetes and syndrome X. Curr. Opin. Endocrinol. Diabetes (1995) 4:307–312.
   Google Scholar
• PFEILE B, DITSCHUNEIT H: Two separate receptors for insulin and insulin-like growth factor on arterial smooth muscle cells. Diabetologia (1981) 20:155–158.
   PubMed Web of Science ®Google Scholar
• YARNELL JVVG, BAKER IA, SWEETMAN PM, et al.: Fibrinogen, viscosity and white blood count are major risk factors for ischemic heart disease. Circulation (1991) 83:836–844.
   PubMed Web of Science ®Google Scholar
• DITSCHUNEIT H, FLECHTNER-MORS M, ADLER G: Fibrinogen in obesity before and after weight reduction. Obesity Res. (1995) 3:43–48.
   PubMedGoogle Scholar
• HENRY RR, WALLACE P, OLEFSKY JM: Effects of weight loss on the mechanisms of hypergly-cemia in obese non-insulin-dependent diabetes. Diabetes (1986) 35:990–998.
   PubMed Web of Science ®Google Scholar
• WING RR, KOESKE R, EPSTEIN LH, et al.: Long-term effects of modest weight loss in type II diabetic patients. Arch. Intern. Med. (1987) 147:1749–1753.
   PubMed Web of Science ®Google Scholar
• SMITH PL, GOLD AR, HAPONIK EF, BLEEKER ER: Weight loss in mildly to morbidly obese patients with obstructive sleep apnea. Ann. Intern. Med. (1985) 103:850–855.
   PubMed Web of Science ®Google Scholar
• CHARUZI I, LAVIE P, PEISER J, PELED R: Bariatric surgery in morbidly obese sleep apnea patients: short- and long-term follow up. Am. 1 Clin. Nutr. (1992) 55:594S–596S.
   Google Scholar
• HULEN BS, EDISON TL, LININGER R: Steroid hormones and risks of breast cancer. Cancer Suppl. (1994) 74:1111–1124.
   PubMed Web of Science ®Google Scholar
• FELSON D, ZHANG Y, ANTHONY J, NAIMARK A, ANDERSON J: Weight loss reduces the risk for subsequent symptomatic knee osteoarthritis in women. Ann Intern. Med. (1992) 116:535–539.
   PubMed Web of Science ®Google Scholar
• MCGOEY BY, DEITEL M, SAPLYS RJF, KLIMAN ME: Effect of weight loss on musculoskeletal pain in the morbidly obese. Bone Joint Surg. (1990) 72B:322–323.
   Google Scholar
• GORRMAKER SL, MUST A, PERRIN JM, SOBOL AM, DIETZ WH: Social and economic Consequences of overweight in adolescence and young adulthood. New Engl. 1 Med. (1993) 329:1008–1012.
   PubMed Web of Science ®Google Scholar
• STUNKARD AJ: The Pain of Obesity. Bull Publishing, Palo Alto, CA (1976).
   Google Scholar
• SERGEANT JD, BLANCHFLOWER DG: Obesity and stature in adolescence and earnings in young adulthood: analysis of a British birth cohort. Arch. Pediatr Adolesc. Med. (1994) 148:681–687.
   PubMed Web of Science ®Google Scholar
• COLDITZ GA: Economic costs of obesity. Am. 1 Clin. Nutr. (1992) 559\(Suppl. 2):5035–5075.
   Google Scholar
• SANNES LJ: Obesity: prospects for emerging theories. Decision Resources (November 1995).
   Google Scholar
• RISSANEN A, HELOVAARA M, KNEKT P, et al.: Risk of disability and mortality due to overweight in a Finish population. Br. Med. 1 (1990) 301:835–837.
   Google Scholar
• WOLF AM, COLDITZ GA: The cost of obesity: the US perspective. Pharmacoeconomics (1994) 5\(Suppl. 1):34–37.
   PubMedGoogle Scholar
• SCOVILLE BA: Review of amphetamine-like drugs by the Food and Drug Administration:
   Google Scholar
• ••clinical data and value judgements. In: Obesity in Perspective. Bray GA (Ed.), Proceedings of theFogarty Conference. US Department of Health, Education and Welfare, Bethesda, MD (1973). NI-T Publication 78–708:441–443.
   Google Scholar
• This is of historic interest.
   Google Scholar
• GOLDSTEIN DJ: Beneficial health effects of modest weight loss. Int. 1 Obesity (1992) 16:397–415.
   PubMed Web of Science ®Google Scholar
• BLACKBURN GL, READ JL: Benefits of reducing - revisited. Postgrad. Med. 1 (1984) 60\(Suppl. 3):13–18.
   Google Scholar
• BRAY GA: Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann. Intern. Med. (1993) 119:707–713.
   PubMed Web of Science ®Google Scholar
• ROBACK PJ, GOLDSTEIN DJ, RAMPEY AN, WILSON MG: Baseline predictors of success when comparing two treatments. Obesity Res. (1994) 2:337–347.
   PubMedGoogle Scholar
• CARO J, SINHA MK, KOLACZYNSKI JW, ZHANG PL, CONSIDINE RV: Leptin: the tale of an ••obesity gene. Diabetes (1996) 45:1455–1462.
   PubMed Web of Science ®Google Scholar
• Review of recent development in understanding the mechanism involved in controlling weight.
   Google Scholar
• SPIEGELMAN BM, FLIER JS: Adipogenesis and obesity: rounding out the big picture. Cell (1996) 87:377–389.
   PubMed Web of Science ®Google Scholar
• LEIBEL RL, ROSENBAUM M, HIRSCH J: Changes in energy expenditure resulting from altered body weight. New Engl. J. Med. (1995) 332:621–628.
   PubMed Web of Science ®Google Scholar
• BANKS WA, KASTIN AJ, HUANG W, JASPAN JB, MANESS LM: Leptin enters the brain by a saturable system independent of insulin. Peptides (1996) 17:305–311.
   PubMed Web of Science ®Google Scholar
• PELLEYMOUNTER MA, CULLEN MJ, BAKER MB, et al.: Effects of the obese gene product on body weight regulation in oblob mice. Science (1995) 269:540–543.
   Google Scholar
• LEBEL C, BOURDEAU A, LAUD et al.: Chronic studies with recombinant human leptin in Beagle dogs. Obesity Res. (1996) 4\(Suppl. 1):365.
   Google Scholar
• WAGNER JD, JAY() MJ, CEFALU WT, et al.: Recombinant human leptin (rHuLEPTIN) reduces body weight and body fat and improves insulin sensitivity in nonhuman primates. Obesity Res. (1996) 4\(Suppl. 1):27S.
   PubMedGoogle Scholar
• CHEN H, CHARLAT L, TARTAGLIA LA, et al.: Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in dbldb mice. Cell (1996) 84:491–495.
   Google Scholar
• CONSIDINE RV, CONSIDINE EL, WILLIAMS CJ, HYDE TM, CARO JF: Identification of incidental sequence polymorphisms and absence of the dbldb mouse and fa/fa rat mutations. Diabetes (1996) 19:992–994.
   Web of Science ®Google Scholar
• MILLER SG, DE VOS P, GUERRE-MILLO M, et al.: The adipocyte specific transcription factor C/EBPalpha modulates human ob gene expression. Proc. Natl. Acad. Sci. USA (1996) 93:5507–5511.
   PubMed Web of Science ®Google Scholar
• HE Y, CHEN H, QUON MJ, REITMAN M: The mouse obese gene. Genomic organization, promoter activity, and activation by CCAAT/enhancer-binding protein alpha. J. Biol. Chem. (1995) 270:28887–28891.
   PubMed Web of Science ®Google Scholar
• TARTAGLIA LA, DEMBRSKI M, WENG X, et al.: Identification and expression cloning of a leptin receptor, OB-R. Cell (1995) 83:1263–1271.
   PubMed Web of Science ®Google Scholar
• GHILARDI N, ZIEGLER S, WIESTNER A, et al.: Defective STAT signaling by the leptin receptor in diabetic mice. Proc. Natl. Acad. Sci. USA (1996) 93:6231–6235.
   PubMed Web of Science ®Google Scholar
• STANLEY BG, KYRKOULI SE, LAMPERT S,LEIBOWITZ SF: Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides (1986) 7:1189–1192.
   PubMed Web of Science ®Google Scholar
• STEPHENS TW, BASINSKI M, BRISTON PK, et al.: The role of neuropeptide Yin the anti-obesity action of the obese gene product. Nature (1995) 377:530–532.
   PubMed Web of Science ®Google Scholar
• GERALD C, WALKER M, CRISCIONE L, et al.: A receptor subtype involved in neuropeptide-Y-induced food intake. Nature (1996) 382:168–170.
   PubMed Web of Science ®Google Scholar
• ERICKSON J, CLEGG K, PALMITER R: Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature (1996) 381:415–418.
   PubMed Web of Science ®Google Scholar
• QU D, LUDWIG D, GAMMELTOFT S, et al.: A role for melanin-concentrating hormone in the central regulation of feeding behavior. Nature (1996) 380:243–247.
   PubMed Web of Science ®Google Scholar
• ARASE K, YORK DA, SHIMIZU H, SHARGILL N, BRAY GA: Effects of corticotropin-releasing factor on food intake and brown adipose tissue thermogenesis in rats. Am. J. PhysioL (1988) 255:E255–259.
   PubMed Web of Science ®Google Scholar
• GUTNIAK M, ORSKOV C, HOLST JJ, AHREN B, EFENDIC S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. New Engl. J. Med. (1992) 326:1316–1322.
   PubMed Web of Science ®Google Scholar
• TURTON MD, O'SHEA D, GUNN I, et al.: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature (1996) 379:69–72.
   PubMed Web of Science ®Google Scholar
• BRAY G: Nutrient intake is modulated by peripheral peptide administration. Obesity Res. (1995) 3\(Suppl. 4):569-572A.
   Google Scholar
• LIEVERSE RJ, MASCLEE AA, JANSEN JB, ROVATI LC, LAMERS CB: Satiety effects of the type A CCK receptor antagonist loxiglumide in lean and obese women. Biol. Psychiatry (1995) 37:331–335.
   PubMed Web of Science ®Google Scholar
• DE ZWAAN M, MITCHELL JE: Opiate antagonists and eating behavior in humans: a review. J. Clin. PharmacoL (1992) 32:1060.
   PubMed Web of Science ®Google Scholar
• YEN TT: Beta-agonists as anti-obesity, antidiabetic and nutrient partitioning agents. Obesity Res. (1995) 3\(Suppl. 4):5315–5365.
   Google Scholar
• CLEMENT K, VAIS SE C, MANNING BS, et al.: Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. New Engl. I Med. (1995) 333:352–354.
   PubMed Web of Science ®Google Scholar
• WIDEN E, LEHTO M, KANNINEN T, et al.: Association of a polymorphism in the beta 3-adren-ergic-receptor gene with features of the insulin resistance syndrome in Finns. New Engl. I Med. (1995) 333:348–351.
   PubMed Web of Science ®Google Scholar
• WALSTON J, SILVER K, BOGARDUS C, et al.: Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. New Engl. I Med. (1995) 333:343–347.
   PubMed Web of Science ®Google Scholar
• HOFFSTEDT J, LONNQVIST F, SHIMIZU M, BLAAK E, ARNER P: Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human mental adipocytes. Int. J. Obesity (1996) 20:428–434.
   Web of Science ®Google Scholar
• GEHLERT DR, GOLDSTEIN DJ, HIPSKIND PA: Treating obesity in the 21st Century. Annual
   Google Scholar
• ••Reports in Medicinal Chemistry, Section IV Immunology, Endocrinology, and Metabolic Diseases.Hagmann (Ed.), Academic Press, Inc. (1996):201–210. This is a brief review of most of the new approaches for treating obesity.
   Google Scholar
• DRENT ML, LARSSON I, WILLIAM-OLSSON T, et al.: Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int. J. Obesity & Related Metab. Disorders (1995) 19:221–226.
   PubMed Web of Science ®Google Scholar
• WEINTRAUB M: Phenylpropanolamine - A Review. John Wiley & Sons, New York (1988).
   Google Scholar
• MORGAN HP, FUNDERBURK FR: Phenylpropanolamine and blood pressure: a review of prospective studies. Am. J. Clin. Nutr. (1992) 55:206S–210S.
   Google Scholar
• GUY-GRAND B, APFELBAUM M, CREPALDI G, et al.: International trial of long-term dexfen-flur amine in obesity. Lancet (1989) 2:1142–1144.
   PubMed Web of Science ®Google Scholar
• ANDERSON T, ASTRUP A, QUAODE F: Dexfenfluramine as adjuvant to a low calorie formula diet in the treatment of obesity: a randomized clinical trial. Int. I Obesity (1993) 16:35–40.
   Google Scholar
• GOLDSTEIN DJ, RAMPEY AH, ROBACK PH, et al.: Efficacy and safety of long-term fluoxetine treatment of obesity - maximizing success. Obesity Res. (1995) 3:481S–490S.
   Google Scholar
• WEINTRAUB M, SUNDARESAN PR, MADAN M, et al.: Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenflu-ramine plus phentermine versus placebo. Clin. Pharmacol. Ther. (1992) 51:586–594.
   PubMed Web of Science ®Google Scholar
• WEINTRAUB M, SUNDARESAN PR, MADAN M, et al: Long-term weight control study II (weeks 34 to 104): an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin. Pharmacol. Ther. (1992) 51:595–601.
   PubMed Web of Science ®Google Scholar
• WEINTRAUB M, SUNDARESAN PR, SCHUSTER B, MOSCUCCI M, STEIN EC: Long-term weight control study Ill (weeks 104 to 156): an open-label study of dose adjustment of fenflu-ramine and phentermine. Clin. Pharmacol. Ther. (1992) 51:602–607.
   PubMed Web of Science ®Google Scholar
• ATKINSON RL, BLANK RC, LOPER JF, SCHUMACHER D, LUTES RA: Combined drug treatment of obesity. Obesity Res. (1995) 3:497S–500S.
   Google Scholar
• ATKINSON RL: Personal communication.
   Google Scholar
• BRAY GA, RYAN DH, GORDON D, et al.: Double-blind randomized trial of sibutr amine in overweight subjects. J Invest. Med. (1995) 43:244A.
   Google Scholar
• FERGUSON JM, BRAY GA, BLACKBURN GL, et al.: Sibutramine - dose response and long-term efficacy in weight loss: a double-blind study. PsychopharmacoL Bull. (1995) 31:568.
   Google Scholar